PMID- 36369635
OWN - NLM
STAT- MEDLINE
DCOM- 20230202
LR  - 20230202
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Linking)
VI  - 117
IP  - 2
DP  - 2023 Feb
TI  - Real-world toxicity and effectiveness of ixazomib, lenalidomide, and 
      dexamethasone in Korean patients with relapsed and/or refractory multiple 
      myeloma.
PG  - 225-235
LID - 10.1007/s12185-022-03479-6 [doi]
AB  - BACKGROUND/AIM: Ixazomib, lenalidomide, and dexamethasone (IRd) have proven 
      efficacy and an excellent safety profile in relapsed and/or refractory multiple 
      myeloma (RRMM). However, there are limited reports on the real-world safety and 
      effectiveness of IRd regimens in Asian patients with RRMM. PATIENTS AND METHODS: 
      This was a retrospective study of 60 patients with RRMM who were treated with 
      IRd. RESULTS: The median patient age was 68 years. Forty percent of patients did 
      not meet the eligibility criteria for the TOURMALINE-MM1 trial. Patients received 
      a median of one prior line of therapy. Non-hematologic adverse events (AEs) were 
      more common than hematologic AEs. The most common AE was skin rash, followed by 
      gastrointestinal toxicities. Most grade 3 or higher AEs were observed in less 
      than 5% of the patients, except for skin rashes and infections. IRd therapy did 
      not aggravate peripheral neuropathy (PN) in 20 of the 24 patients with 
      pre-existing peripheral neuropathy. The overall response rate was 85%. After a 
      median follow-up of 26.3 months, the median progression-free survival was 
      25.9 months and overall survival was not reached. CONCLUSION: Ixazomib and Rd 
      combination therapy had a comparable toxicity profile and effectiveness in 
      real-world RRMM patients.
CI  - (c) 2022. Japanese Society of Hematology.
FAU - Lee, Ji Hyun
AU  - Lee JH
AUID- ORCID: 0000-0003-2341-4911
AD  - Department of Internal Medicine, Dong-A University College of Medicine, Busan, 
      Republic of Korea.
FAU - Kim, Sung-Hyun
AU  - Kim SH
AD  - Department of Internal Medicine, Dong-A University College of Medicine, Busan, 
      Republic of Korea.
FAU - Kim, Hye Ryeon
AU  - Kim HR
AD  - Department of Internal Medicine, Dong-A University College of Medicine, Busan, 
      Republic of Korea.
FAU - Min, Chang-Ki
AU  - Min CK
AD  - Department of Hematology, Seoul St. Mary's Hematology Hospital, College of 
      Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
FAU - Lee, Je-Jung
AU  - Lee JJ
AD  - Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 
      Chonnam National University Medical School, Hwasun, Republic of Korea.
FAU - Shin, Ho-Jin
AU  - Shin HJ
AD  - Division of Hematology-Oncology, Department of Internal Medicine, School of 
      Medicine, Medical Research Institute, Pusan National University Hospital, Busan, 
      Republic of Korea.
FAU - Jo, Jae-Cheol
AU  - Jo JC
AD  - Department of Hematology and Oncology, Ulsan University Hospital, University of 
      Ulsan College of Medicine, Ulsan, Republic of Korea.
FAU - Lee, Ji Yun
AU  - Lee JY
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, Republic of Korea.
FAU - Moon, Joon Ho
AU  - Moon JH
AD  - Division of Hematology-Oncology, Department of Internal Medicine, School of 
      Medicine, Kyungpook National University, 130, Dongduk-Ro, Jung-Gu, Daegu, 41944, 
      Republic of Korea. jhmoon@knu.ac.kr.
FAU - Kim, Kihyun
AU  - Kim K
AD  - Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University 
      School of Medicine, Samsung Medical Center, 81, Irwon-Ro, Gangnam-Gu, Seoul, 
      06351, Republic of Korea. kihyunkimk@gmail.com.
LA  - eng
GR  - NRF-2016R1A5A2007009/National Research Foundation of Korea/
GR  - NRF-2017R1C1B5014853/National Research Foundation/
PT  - Journal Article
DEP - 20221111
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - F0P408N6V4 (Lenalidomide)
RN  - 71050168A2 (ixazomib)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - 0 (Boron Compounds)
SB  - IM
MH  - Humans
MH  - Aged
MH  - Lenalidomide
MH  - *Multiple Myeloma
MH  - Retrospective Studies
MH  - Dexamethasone
MH  - Boron Compounds/adverse effects
MH  - *Peripheral Nervous System Diseases/chemically induced
MH  - *Exanthema/chemically induced
MH  - Republic of Korea/epidemiology
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
OTO - NOTNLM
OT  - Asia
OT  - Ixazomib
OT  - Lenalidomide
OT  - Multiple myeloma
OT  - Real-world
OT  - Refractory
OT  - Relapsed
EDAT- 2022/11/13 06:00
MHDA- 2023/02/03 06:00
CRDT- 2022/11/12 00:50
PHST- 2022/06/08 00:00 [received]
PHST- 2022/10/23 00:00 [accepted]
PHST- 2022/10/21 00:00 [revised]
PHST- 2022/11/13 06:00 [pubmed]
PHST- 2023/02/03 06:00 [medline]
PHST- 2022/11/12 00:50 [entrez]
AID - 10.1007/s12185-022-03479-6 [pii]
AID - 10.1007/s12185-022-03479-6 [doi]
PST - ppublish
SO  - Int J Hematol. 2023 Feb;117(2):225-235. doi: 10.1007/s12185-022-03479-6. Epub 
      2022 Nov 11.